SYNDAX PHARMACEUTICALS INC
SNDXNASDAQTrading Snapshot
- Day Range
- $18.14 – $18.38
- 52-Week Range
- $12.99 – $25.59
- Volume
- $2.73B
- Avg Volume
- $2.21B
- Shares Outstanding
- 88.6M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $172M
- Last Q Revenue
- $73M
- P/E Ratio
- -7.2
- P/S Ratio
- 6.4x
- EPS (TTM)
- $-2.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.0%
Why Investors Own SNDX
- ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SYNDAX PHARMACEUTICALS INC
SNDX
StockOtter · stockotter.spaceAbout SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax Pharmaceuticals remains a "Strong Buy," driven by label expansion and robust revenue growth for Revuforj and Niktimvo. Company achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts
Syndax Pharmaceuticals, Inc. is positioned for significant growth, driven by Revuforj and Niktimvo, with management reiterating $2B+ U.S. peak sales for Revuforj. Recent SAVE trial data for Revuforj in AML shows 88% ORR
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Compa
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
BlackRock Inc. bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 9,020,006 shares of the company's stock,